Cargando…
Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
INTRODUCTION: Immune-based and antibody-drug conjugate therapies have shown promise in the treatment of patients with small cell lung cancer (SCLC). However, better predictive biomarkers are needed for selection of the appropriate SCLC patients for these advanced therapies and also for evaluation of...
Autores principales: | Regzedmaa, Orgilmaa, Li, Ying, Li, Yongwen, Zhang, Hongbing, Wang, Jin, Gong, Hao, Yuan, Yin, Li, Weiting, Liu, Hongyu, Chen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877464/ https://www.ncbi.nlm.nih.gov/pubmed/31819500 http://dx.doi.org/10.2147/OTT.S216362 |
Ejemplares similares
-
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019) -
miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene
por: Li, Yongwen, et al.
Publicado: (2018) -
HOTAIR promotes gefitinib resistance through modification of EZH2 and silencing p16 and p21 in non-small cell lung cancer
por: Li, Weiting, et al.
Publicado: (2021) -
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
por: Gong, Hao, et al.
Publicado: (2020) -
Viscera Characteristics of MSTN-Edited Heterozygous Pigs
por: Pei, Yangli, et al.
Publicado: (2022)